In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Invivyd, with a price target of $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Invivyd’s strategic positioning and growth potential. The company’s VYD2311, a next-generation monoclonal antibody, is positioned as a scalable vaccine-like prophylaxis with a favorable safety profile and significant potency improvements over existing treatments. This product is expected to transition from intravenous to intramuscular delivery, enhancing convenience and scalability, which could expand its market reach.
Additionally, Invivyd’s commercial strategy is supported by the current uptake of PEMGARDA under emergency use authorization, which lays the groundwork for broader adoption of antibody prophylaxis. The company’s diversification into other areas such as respiratory syncytial virus, measles, and Lyme disease further reinforces its long-term growth potential. These efforts indicate Invivyd’s ambition to transition from a COVID-19-focused company to a multi-asset entity, which underpins Trucchio’s positive outlook and Buy rating.